West Pharmaceutical Services (NYSE:WST) said today that it finished a 60,000 square foot expansion of its contract manufacturing facility near Mulhuddart, County Dublin in Ireland. The expansion is a response to customer demand for medical device manufacturing, especially in the area of diabetes, the company reported.

West anticipates 100 new jobs will be added to the business over 5 years because of the expansion. Additional capacity in Dublin will grow the company’s medical device contract manufacturing business, focusing on molding and assembly solutions for the production of medical devices like auto-injectors and glucose monitoring systems.

The company also said that its contract manufacturing business, which was formerly known as The Tech Group, will align with the West brand.

“As the healthcare market becomes increasingly complex, West is advancing our core competencies in the development, manufacturing and final packaging of complex drug delivery systems and diagnostic devices for our customers,” senior VP & chief commercial officer Karen Flynn said in prepared remarks. “We are excited about the growth and expansion we are experiencing in both our contract manufacturing business in Dublin as well as our proprietary products business in Waterford, both of which will support increasing demand from our global customer base.”

“We are very pleased with West’s commitment to furthering operations in Ireland,” Ireland’s minister for jobs, enterprise & innovation Mary Mitchell O’Connor added. “With this most recent expansion in Dublin and the company’s previously announced investment in Waterford, West is affirming its presence as an important employer in Ireland. I am delighted with this new investment, which strongly aligns with the Government’s ongoing strategy to attract investment in high-quality, high-value, medical device manufacturing to Ireland. We look forward to strengthening our relationship with West.”

“IDA’s life science sector continues to grow from strength-to-strength and this investment by West is a good example of the potential for convergence across the life sciences sector,” IDA Ireland CEO Martin Shanahan said. “Ireland has seen hundreds of millions invested in recent years in the development and manufacturing of new injectable drugs for diabetes, cardiovascular disease, autoimmune disease and cancer. The patients who will benefit from these exciting new drugs will also benefit from West’s innovation in drug delivery devices. IDA welcomes this investment and looks forward to continuing to work with West and their partner biotech companies in further developing the Irish cluster.”